Bli medlem
Bli medlem

Du är här

2016-03-15

Basilea Pharmaceutica AG: Basilea issues agenda for Annual General Meeting of Shareholders

Basilea Pharmaceutica AG / Basilea issues agenda for Annual General Meeting of
Shareholders. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
* Dr. Martin Nicklasson has determined not to stand for re-election as
Chairman but will stand for re-election as Member of the Board
* Domenico Scala nominated as new Chairman of the Board

Basel, Switzerland, March 15, 2016

- Basilea Pharmaceutica Ltd. (SIX: BSLN) issued on its company website today
the agenda for its 2016 Annual General Meeting of Shareholders (AGM) which
will be held on April 21, 2016 in Basel. The full invitation including the
agenda will be published in the Swiss Official Gazette of Commerce in due
course.

The Chairman of the Board, Dr. Martin Nicklasson, has informed the board that
he will not stand for re-election as Chairman at the 2016 AGM. Dr. Nicklasson
will stand for re-election as a board member. Dr. Nicklasson has been
Chairman of the Board since 2013. During his tenure, Basilea successfully
gained regulatory approval for and launched CRESEMBA®and Zevtera®. The board
thanks Dr. Nicklasson for his contributions as Chairman.

The board proposes that the shareholders elect Domenico Scala as the new
Chairman of the Board. Mr. Scala, a Swiss and Italian citizen, has served as
a Member of Basilea's Board of Directors and its Vice-Chairman since 2011.
From 2007 to 2011, he was President and Chief Executive Officer of Nobel
Biocare Holding AG and from 2003 to 2007, he was Chief Financial Officer of
Syngenta International AG. From 1995 to 2003, Mr. Scala served in various
senior leadership positions at Roche Holding AG. Mr. Scala is Chairman of the
Audit and Compliance Committee of FIFA (Fédération Internationale de Football
Association) and President of BaselArea. He graduated from the University of
Basel with a degree in economics and holds Executive Development degrees from
INSEAD and London Business School.

According to Basilea's current Organizational Regulations, the term of each
member of the Board of Directors ends effective as per the AGM immediately
following completion of his or her 70th year of age. For this reason, Mr.
Hans-Beat Gürtler, board member since 2009, will not stand for re-election at
the 2016 AGM. The board thanks Mr. Gürtler for his commitment to Basilea and
his service on the board. The remaining current board members will stand for
re-election at the AGM: Prof. Daniel Lew, Dr. Martin Nicklasson, Dr. Thomas
M. Rinderknecht, Mr. Domenico Scala, Mr. Steven Skolsky, and Dr. Thomas
Werner.

The full agenda can be viewed on the company website. Printed invitations will
be sent by post to shareholders, and those shareholders and usufructuaries
who as per April 8, 2016 are recorded in the share register with voting
rights are entitled to participate and exercise their voting rights at the
AGM.

About Basilea

Basilea Pharmaceutica Ltd. is a biopharmaceutical company developing products
that address increasing resistance and non-response to current treatment
options in the therapeutic areas of bacterial infections, fungal infections
and cancer. The company uses the integrated research, development and
commercial operations of its subsidiary Basilea Pharmaceutica International
Ltd. to discover, develop and commercialize innovative pharmaceutical
products to meet the medical needs of patients with serious and potentially
life-threatening conditions. Basilea Pharmaceutica Ltd. is headquartered in
Basel, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN).
Additional information can be found at Basilea's websitewww.basilea.com.

Disclaimer

This communication expressly or implicitly contains certain forward-looking
statements concerning Basilea Pharmaceutica Ltd. and its business. Such
statements involve certain known and unknown risks, uncertainties and other
factors, which could cause the actual results, financial condition,
performance or achievements of Basilea Pharmaceutica Ltd. to be materially
different from any future results, performance or achievements expressed or
implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is
providing this communication as of this date and does not undertake to update
any forward-looking statements contained herein as a result of new
information, future events or otherwise.

For further information, please contact:

-------------------------------------------------
| Peer Nils Schröder, PhD |
|Head Public Relations&Corporate Communications |
|+41 61 606 1102 |
|media_relations@basilea.com |
| |
|investor_relations@basilea.com |
-------------------------------------------------
This press release can be downloaded fromwww.basilea.com.

Press release (PDF)
http://hugin.info/134390/R/1994256/734331.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Basilea Pharmaceutica AG via Globenewswire

HUG#1994256

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.